0.961
price up icon0.20%   0.0019
after-market 시간 외 거래: .90 -0.061 -6.35%
loading
전일 마감가:
$0.9591
열려 있는:
$0.91
하루 거래량:
239.24K
Relative Volume:
0.05
시가총액:
$12.76M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.0628
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
-10.19%
1개월 성능:
-25.50%
6개월 성능:
-61.87%
1년 성능:
-82.37%
1일 변동 폭
Value
$0.91
$0.9699
1주일 범위
Value
$0.91
$1.09
52주 변동 폭
Value
$0.3975
$5.91

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
명칭
Moleculin Biotech Inc
Name
전화
713-300-5160
Name
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
직원
17
Name
트위터
@moleculinbio
Name
다음 수익 날짜
2024-12-08
Name
최신 SEC 제출 서류
Name
MBRX's Discussions on Twitter

MBRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MBRX
Moleculin Biotech Inc
0.961 12.76M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-12 다운그레이드 Maxim Group Buy → Hold
2022-07-18 재개 Oppenheimer Outperform

Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스

pulisher
08:41 AM

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance

08:41 AM
pulisher
05:51 AM

Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo

05:51 AM
pulisher
Apr 01, 2025

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan

Apr 01, 2025
pulisher
Mar 29, 2025

Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN

Mar 29, 2025
pulisher
Mar 28, 2025

What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus.com

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Promising Advancements in Moleculin Biotech’s Annamycin Pivotal Trial Drive Buy Rating and $8 Price Target - TipRanks

Mar 24, 2025
pulisher
Mar 21, 2025

Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - StockTitan

Mar 19, 2025
pulisher
Mar 18, 2025

Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Mar 18, 2025
pulisher
Mar 13, 2025

Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

5 Major Growth Catalysts: Moleculin Biotech CEO Reveals 2025 Strategic Roadmap - Stock Titan

Mar 11, 2025
pulisher
Mar 10, 2025

Moleculin to Present at the 37th Annual ROTH Conference - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Moleculin to Present at the 37th Annual ROTH Conference -March 10, 2025 at 08:46 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - GuruFocus.com

Mar 10, 2025
pulisher
Mar 06, 2025

Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech - openPR

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Announces Additional Annamycin Patent Allowances to En - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Biotech to be granted new patents for Annamycin - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - PR Newswire

Mar 06, 2025
pulisher
Mar 06, 2025

What is HC Wainwright’s Forecast for MBRX Q4 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Moleculin Receives Positive FDA Guidance for Acceleration of its - GuruFocus.com

Mar 04, 2025
pulisher
Mar 04, 2025

Moleculin Biotech’s (MBRX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium - Marketscreener.com

Mar 03, 2025

Moleculin Biotech Inc (MBRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):